Evidence map›Paper›PMID 35704618›Full record

ArticlePloS one2022

Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice.

Sotaro Ozaka, Akira Sonoda, Shimpei Ariki, Mizuki Minata, Naganori Kamiyama, Shinya Hidano, Nozomi Sachi, Kanako Ito, Yoko Kudo, Astri Dewayani and 12 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Sotaro OzakaDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Akira SonodaDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Shimpei ArikiDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Mizuki MinataDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Naganori KamiyamaDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Shinya HidanoDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Nozomi SachiDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Kanako ItoDepartment of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Yoko KudoDepartment of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Astri DewayaniDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.ORCID 0000-0001-9577-8373
Thanyakorn ChalalaiDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Takashi OzakiDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Yasuhiro SogaDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Chiaki FukudaDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Kazuhiro MizukamiDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Shiori IshizawaTsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan.
Mitsue NishiyamaTsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan.ORCID 0000-0002-3878-1290
Naoki FujitsukaTsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan.
Sachiko MogamiTsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan.
Kunitsugu KubotaTsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan.
Kazunari MurakamiDepartment of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Takashi KobayashiDepartment of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Oita, Japan.ORCID 0000-0002-9069-5736
Oita University · JPTsumura Research Institute (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotics disrupt normal gut microbiota and cause dysbiosis, leading to a reduction in intestinal epithelial barrier function. Disruption of the intestinal epithelial barrier, which is known as "leaky gut", results in increased intestinal permeability and contributes to the development or exacerbation of gastrointestinal diseases such as inflammatory bowel disease and irritable bowel syndrome. We have previously reported on a murine model of intestinal epithelial barrier dysfunction associated with dysbiosis induced by the administration of ampicillin and vancomycin. Saireito, a traditional Japanese herbal medicine, is often used to treat autoimmune disorders including ulcerative colitis; the possible mechanism of action and its efficacy, however, remains unclear. In this study, we examined the efficacy of Saireito in our animal model for leaky gut associated with dysbiosis. C57BL/6 mice were fed a Saireito diet for the entirety of the protocol (day1-28). To induce colitis, ampicillin and vancomycin were administered in drinking water for the last seven consecutive days (day22-28). As previously demonstrated, treatment with antibiotics caused fecal occult bleeding, cecum enlargement with black discoloration, colon inflammation with epithelial cell apoptosis, and upregulation of pro-inflammatory cytokines. Oral administration of Saireito significantly improved antibiotics-induced fecal occult bleeding and cecum enlargement by suppressing inflammation in the colon. Furthermore, Saireito treatment ensured the integrity of the intestinal epithelial barrier by suppressing apoptosis and inducing cell adhesion proteins including ZO-1, occludin, and E-cadherin in intestinal epithelial cells, which in turn decreased intestinal epithelial permeability. Moreover, the reduced microbial diversity seen in the gut of mice treated with antibiotics was remarkably improved with the administration of Saireito. In addition, Saireito altered the composition of gut microbiota in these mice. These results suggest that Saireito alleviates leaky gut caused by antibiotic-induced dysbiosis. Our findings provide a potentially new therapeutic strategy for antibiotic-related gastrointestinal disorders.

Indexed as

ColitisColitis, UlcerativeAmpicillinAnimalsAnti-Bacterial AgentsDisease Models, AnimalDrugs, Chinese HerbalDysbiosisHerbal MedicineInflammationIntestinal MucosaJapanMiceMice, Inbred C57BLVancomycinAmpicillinAnti-Bacterial AgentsDrugs, Chinese Herbalsairei-toVancomycin

Identifiers

PMID35704618
PMCPMC9200308
OpenAlexW4282929376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.